mAb Industry in China : Biosimilars vs Innovative Biologics
21st March 2019 | 4PM China Standard Time, 10AM GMT | Dr. Joe X Zhou, CEO at Genor Biopharma, Walvax Bio Group and Floris De Smet Bioprocess Technical Support & Field Marketing at Sartorius Stedim Biotech |BOOK FREE SEAT
Following patent cliffs for Erbitux, Rituxan, Sandosta_n and several big blockbusters, Herceptin, Avastin are now among the next biosimilar targets. This is creating huge potential for biosimilars, prompting innovators to shift their focus to target more emerging markets which remain untapped for many companies. In this presentation, Joe will be sharing with you his vision of the biosimilars market with a focus on China. He will also discuss key considerations for mAb and biologics therapeutic development, providing a broad overview of challenges and opportunities presenting in the market.
1. Landscape changes of mAb therapeutics
2. New targets and process/manufacturing innovation
3. Key consideration of mAb industry in China
4. Case study: Development strategies of PD-1 mAb as anti-tumor therapeutics in China for global market
Presented by Dr Joe X Zhou, CEO at Genor Biopharma, Walvax Bio Group
Previously, Dr. Zhou was a Scientific Director at Amgen, Thousand Oaks, USA. His over 20-years’ experience of process development, multiple project management capacity in cGMP and non-GMP reproducible purification/production of protein/antibody therapeutics made Dr. Zhou many times as Project Process Team Leader/Project Team Leader/Cross Functional Core Investigation Teams Leaders at Amgen in the past. Dr. Zhou was awarded as 2007 Amgen’s “Excellence in Science and Engineering” for his major achievement and leadership on photo-oxidation on monoclonal antibody yellowing. He has oral presentation over 150 times globally with more than 50 publications and about 20 patents on bioprocess, and selected by Amgen as a visiting professor teaching the GMP Master’s Degree Program at PKU, People’s Republic of CHINA since 2007.
Sponsored by Sartorius Stedim Biotech
Presented by Floris De Smet, Bioprocess Technical Support & Field Marketing at Sartorius Stedim Biotech
Floris De Smet has over 10 years of experience in the bioprocessing industry. He has been with Sartorius since 2007 in various sales and marketing positions in Europe, US and Asia, including global key account management, PD consultancy and strategic marketing. In his current tenure, he leads the field team of application specialist and marketing managers in China. His topics of interest include molecule lifecycle management, alliance management, corporate business development and strategic marketing. Floris holds an M.Sc. and M.Econ., both from Ghent University, Belgium.